NASDAQ · SPRY
Healthcare · Biotechnology
$3.38
Down-$0.28 (-7.65%)
Updated Oct 31, 2026, 11:07 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SPRY
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
SPRY closed at $3.38 after 21 trading sessions, down 16.95% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $3.62 | $3.79 | $3.34 | $3.38 | 1.76M |
| Oct 29, 2026 | $3.70 | $3.90 | $3.625 | $3.66 | 2.04M |
| Oct 28, 2026 | $3.69 | $3.73 | $3.525 | $3.65 | 2.53M |
| Oct 27, 2026 | $3.92 | $3.95 | $3.64 | $3.73 | 1.64M |
| Oct 26, 2026 | $4.03 | $4.09 | $3.90 | $3.92 | 1.43M |
| Oct 23, 2026 | $4.28 | $4.28 | $3.995 | $4.03 | 1.52M |
| Oct 22, 2026 | $4.13 | $4.355 | $4.13 | $4.32 | 1.79M |
| Oct 21, 2026 | $4.32 | $4.42 | $4.165 | $4.18 | 1.01M |
| Oct 20, 2026 | $4.25 | $4.44 | $4.225 | $4.29 | 1.54M |
| Oct 19, 2026 | $4.07 | $4.32 | $4.00 | $4.23 | 1.51M |
| Oct 16, 2026 | $4.08 | $4.08 | $3.8101 | $4.02 | 2.33M |
| Oct 15, 2026 | $3.99 | $4.095 | $3.94 | $4.07 | 2.22M |
| Oct 14, 2026 | $4.01 | $4.095 | $3.885 | $3.93 | 1.73M |
| Oct 13, 2026 | $4.18 | $4.18 | $3.995 | $4.05 | 1.55M |
| Oct 12, 2026 | $4.20 | $4.27 | $4.06 | $4.18 | 1.27M |
| Oct 9, 2026 | $4.53 | $4.555 | $4.20 | $4.23 | 1.26M |
| Oct 8, 2026 | $4.35 | $4.635 | $4.21 | $4.56 | 1.59M |
| Oct 7, 2026 | $4.24 | $4.4017 | $4.2047 | $4.36 | 1.3M |
| Oct 6, 2026 | $4.31 | $4.31 | $4.08 | $4.295 | 1.22M |
| Oct 5, 2026 | $4.13 | $4.395 | $4.03 | $4.29 | 1.62M |
| Oct 2, 2026 | $4.16 | $4.27 | $3.985 | $4.07 | 1.83M |
The latest Smart Investors Daily articles mentioning SPRY.
Company
Market Activity
Research & News
SPRY research
Company profile and research snapshot.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 25, 2026 | Leerink Partners | Outperform | — |
| May 28, 2026 | Cantor Fitzgerald | Overweight | — |
| Sep 4, 2025 | Roth Capital | Buy | — |
| Mar 7, 2025 | Scotiabank | Sector Outperform | — |
| Jan 14, 2025 | Raymond James | Strong Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 30, 2026
Aquestive Therapeutics offers a differentiated epinephrine product, Anaphylm, but faces pricing and market share headwinds. Learn why AQST stock is a hold.
Yahoo · Sep 1, 2026
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in the following September investor conferences. Wells Fargo Healthcare Conference 1x1 Investor Meetings: Wednesday, September 9, 2026Location: Boston Cantor Global Healthcare Conference Fireside Chat: Fr
SeekingAlpha · Aug 18, 2026
ARS Pharma has experienced a >65% decline since my previous 'Hold' rating, reflecting significant commercialization challenges. Click for more on SPRY stock.
SeekingAlpha · Aug 14, 2026
ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call August 13, 2026 4:30 PM EDTCompany ParticipantsDonn Casale - CEO, President & DirectorKathleen...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SPRY.
